August 2026

GR Engineering Services secured $100 million through a heavily supported institutional placement priced at $6.10 per share, alongside a $10 million Share Purchase Plan for retail investors. The capital raise aims to bolster the balance sheet ahead of a busy contract delivery phase.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Stakk is on the cusp of completing its US$63 million acquisition of ParaScript, having secured shareholder approval and completed a A$27 million placement. The combined entity is poised to meet or exceed FY2027 revenue and EBITDA targets, reinforcing its digital trust platform strategy.

Hearts and Minds Investments Limited (HM1) saw its profit after tax drop 57% to $46.4 million for FY26, amid a portfolio return slowdown to 5.2%. The company declared a 10-cent fully franked final dividend and maintained its $11.4 million commitment to Australian medical research.

Imagion Biosystems has signed key CRO work orders and completed manufacturing of its MagSense HER2 Imaging Agent, advancing its Phase 1b/2 clinical trial targeting HER2+ breast cancer. Trial initiation is underway with seven prospective sites, including contract talks with the first US clinical site.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

L1 Long Short Fund Limited (ASX:LSF) posted a standout FY26 with a 45.4% net portfolio return, driving a 538% jump in net profit after tax to $635 million and a 22% CAGR in dividends since IPO. The fund also released its inaugural climate-related disclosures, affirming resilience amid evolving risks.

Strata Investment Holdings delivered a £16.48 million comprehensive profit for H1 2026, driven by a strong revaluation of its investment portfolio and maiden royalty income from Botswana copper assets.

Nickel Industries surged to a US$74 million profit in H1 2026, driven by higher nickel prices, expanded mining quotas, and strategic HPAL investments including first nickel cathode production at ENC.

Prime Financial Group Ltd grew revenue by 22% to $60.5 million in FY26, driven by acquisitions and core business expansion. However, net profit after tax fell 15%, impacted by a higher tax rate and elevated operating costs.

Verity Resources has renewed four prospecting licences in Botswana, safeguarding its stake in high-grade copper-silver and nickel-copper-PGE projects including Airstrip, Dibete, and Maibele North for another two years.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

IVE Group posted a mixed FY26 with a 1.8% revenue decline but underlying profit growth, strategic acquisitions, and notable progress in AI commercialization and climate disclosures.

Sierra Nevada Gold (ASX: SNX) has completed a $12.85 million capital raise to fund an aggressive Phase 2 drilling campaign at its As Safra Copper-Gold Project in Saudi Arabia, supported by strong institutional backing.

Atlas Pearls Ltd (ASX: ATP) faced a tough FY26 with revenue down 42% to $25.8 million and a net loss of $7.9 million, driven by lower pearl quality and softer market conditions. Despite this, the company seeded a record number of oysters and declared a fully franked final dividend of 0.45 cents per share.

Urbanise.com Limited reported 14.3% revenue growth to $15 million in FY2026, significantly narrowing its net loss to $0.9 million while advancing a NAB partnership pilot and launching AI features.

Resimac Group Ltd delivered a 42% jump in statutory profit for FY26 despite flat revenue, driven by strong home loan growth and improved margins, while raising its final dividend to 6 cents per share.

Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Minrex Resources has reported strong assay results from the first ten infill drill holes at its Barje deposit, revealing shallow, high-grade gold-silver mineralisation that supports a low-strip, high-margin open pit scenario. The company is boosting its 2026 drilling program to 9,000 metres to explore extensions along the Barje-Liska corridor.

Rapid Critical Metals has reported exceptional silver assay results from its Webbs Silver Project in NSW, including a standout 4m at 1,230 g/t AgEQ intercept and a significant 300m southern extension of mineralisation. The company is accelerating drilling with a third rig and advancing resource growth plans.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.